Pierian Biosciences

#CancerIntel: #Immunotherapy -- a new hope for #breastcancer treatment https://bit.ly/2CC3JQ7 #BreastCancerAwarenessMonth #personalized #medicine

Liverpool plays a key role as a hub for national health research, with its medical facilities leading the way in studies and testing across a wide range of conditions, treatments, and diseases, which includes cancer treatments. Given the outstanding cancer research being conducted in the city, Liverpool was the ideal location for our UK laboratories. The city is home to several renowned cancer treatment and research centers, such as the Liverpool Cancer Research Institute, the prestigious Clatterbridge Cancer Centre, Liverpool University Biobank (LUB), Cancer Research UK’s Cancer Trial Units, and the Royal Liverpool University Hospital. #biosciences #cancerresearch #liverpool #healthstudies #laboratory

Our goal is to extend personalised medicine beyond initial treatments, ensuring tailored approaches for every cancer recurrence in the same patient. We deliver clinically actionable diagnostic information, empowering healthcare providers to personalise treatment for patients with cancer and autoimmune diseases. By providing this critical information, Pierian Biosciences is committed to enhancing the quality of life for cancer patients through personalized treatment at every stage. #PersonalisedMedicine #CancerTreatment #HealthcareInnovation #PierianBiosciences #PatientCare

ImmunoINTEL is our advanced flow cytometry-based platform that offers phenotypic characterisation and quantitative functional analysis of tumour and immune populations within tumour samples and relevant tissues. With over 50 years of expertise in quantitative flow cytometry, we deliver precise assays for biopharmaceutical R&D activities, Phase I-IV clinical trials, and clinical diagnostics. Our highly automated, plate-based flow cytometry workflow ensures reproducible and high-throughput evaluation of cells from dissociated solid tumours, hematologic cancers, and autoimmune diseases. #ImmunoINTEL?#CancerResearch #ClinicalTrials #PierianBiosciences #Innovation

At Pierian Biosciences, our mission is to transform the cancer treatment experience for both patients and providers. We're dedicated to delivering clinically actionable diagnostic information, empowering healthcare providers to personalize treatment for patients with cancer and autoimmune diseases. Pierian Biosciences is committed to enhancing the quality of life for cancer patients through personalized treatment at every stage. #PersonalisedMedicine #CancerTreatment #HealthcareInnovation #PierianBiosciences #PatientCare

ChemoINTEL is a functional, multi-parametric chemosensitivity assay that measures real-time kinetic molecular and morphologic apoptotic responses in isolated tumour cells. Whether dealing with dissociated solid tumours or hematologic cancers, ChemoINTEL evaluates the effects of cytotoxic agents, targeted molecular therapeutics, biologics, and combination therapies. At Pierian Biosciences, we’ve advanced our biopharmaceutical support services by implementing an automated, 384-well based imaging platform. From Pre-Clinical through Phase IV clinical trials, our highly automated, plate-based imaging system ensures precise and efficient evaluation of cells from both solid tumours and hematologic cancers. #CancerResearch #Biotech #ClinicalTrials #PierianBiosciences #Innovation

We aim to deliver the most innovative, treatment-directing testing possible while providing analytical approaches that lead the way for personalised medicine and translational science. At Pierian Biosciences we have implemented 2 platforms to aid in the testing, analysis, and evaluation of tumour samples. ImmunoINTEL - a flow cytometry-based platform providing phenotypic characterisation and quantitative functional interrogation of tumour and immune populations within a tumour sample and relevant tissue. ChemoINTEL - is a functional multi-parametric chemo-sensitivity assay measuring the real-time kinetic molecular and morphologic apoptotic response in isolated tumour cells (dissociated solid tumours or hematologic cancers) induced by cytotoxic agents, targeted molecular therapeutics, biologics, or combination therapy. Pierian Biosciences is dedicated to providing clinically actionable diagnostic information enabling healthcare providers to personalise treatment of patients with cancer and auto-immune disease. #chemotherapy #immunotherapy #cancerresearch #bioscience #healthcare

The City of Liverpool serves as a central hub for national health studies, with the local medical facilities being prevalent towards research and testing for a wide variety of conditions, treatments, and illnesses, which includes cancer treatment. Based on the work we deliver; Liverpool was an appropriate choice for our UK laboratories given the wealth of top-level cancer research that the city provides. Liverpool is also the home to numerous central locations that focus on cancer treatment and cancer research, including Liverpool Cancer Research Institute, the world-class Clatterbridge Cancer Centre, Liverpool University Biobank (LUB), Cancer Research UK’s Cancer Trial Units, and the Royal Liverpool University Hospital. #biosciences #cancerresearch #liverpool #healthstudies #laboratory

We are Pierian Biosciences. Our mission is profoundly changing the cancer treatment experience for patients and providers. Dedicated to providing clinically actionable diagnostic information enabling healthcare providers to personalise treatment of patients with cancer and auto-immune disease. The goal of personalised medicine is not just to guide the initial treatment of each patient’s cancer, but instead personalisation is needed for each cancer recurrence in the same patient. Pierian Biosciences is focused on enhancing the quality of life for cancer patients by providing actionable information to allow personalised treatment every time cancer occurs. #bioscience #cancerresearch #healthcare #cancertreatment

ChemoINTEL is a functional multi-parametric chemosensitivity assay measuring the real-time kinetic molecular and morphologic apoptotic response in isolated tumour cells (dissociated solid tumours or hematologic cancers) induced by cytotoxic agents, targeted molecular therapeutics, biologics, or combination therapy. At Pierian Biosciences we have implemented an automated, 384-well based imaging platform to provide biopharmaceutical support services for Pre-Clinical thru Phase IV clinical trials. Using a highly-automated, plate-based imaging system, Pierian Biosciences provides the following for evaluation of cells from dissociated solid tumours or hematologic cancers. #chemotherapy #bioscience #cancerresearch #healthcareproviders